A multicentre, double-blind, randomised, parallel-group, Phase II study to assess efficacy and safety of D9421-C 9 mg and 15 mg versus placebo in Japanese patients with active Crohn's Disease
D9421-C, 9mg, D9421-C, 15mg, Placebo
18 Years - 65 Years
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jul 2012 by AstraZeneca Pharmaceuticals
No locations available
|Active Comparator: 1|
D9421-C 9 mg
Drug: D9421-C, 9mg
D9421-C 9 mg was given once daily for 8 weeks.
|Active Comparator: 2|
D9421-C 15 mg
Drug: D9421-C, 15mg
D9421-C 15 mg was given once daily for 8 weeks.
|Placebo Comparator: 3|
D9421-C matching placebo was given once daily for 8 weeks.